Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGOH2P (Mago homolog 2, pseudogene) is a segment of DNA homologous to the protein-coding mago homolog genes but contains mutations that abolish its ability to encode a functional protein[1][2][4]. Pseudogenes like MAGOH2P arise through gene duplication or retrotransposition and subsequent disabling mutations[3][4]. Although a minority of pseudogenes may have regulatory roles via RNA in specific cases, there is no evidence that MAGOH2P has such a function. Pseudogenes can pose technical challenges in genetic studies, such as complicating genetic assays through sequence similarity, but are not considered drug targets, receptors, or functional molecules for therapeutic modulation[2][4]. MAGOH2P is cataloged in genomic databases for reference and annotation purposes only[1].
None (no drugs or therapies act on this pseudogene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mago homolog 2, pseudogene (MAGOH2P).